乳腺癌患者內(nèi)分泌治療服藥監(jiān)控平臺的設(shè)計及應(yīng)用
發(fā)布時間:2017-12-27 00:28
本文關(guān)鍵詞:乳腺癌患者內(nèi)分泌治療服藥監(jiān)控平臺的設(shè)計及應(yīng)用 出處:《中華護理雜志》2017年03期 論文類型:期刊論文
更多相關(guān)文章: 乳腺腫瘤 醫(yī)院信息系統(tǒng) 病人依從 生活質(zhì)量
【摘要】:目的探索基于乳腺癌內(nèi)分泌服藥監(jiān)控平臺的護士隨訪對接受內(nèi)分泌治療的乳腺癌患者服藥依從性和生活質(zhì)量的影響。方法構(gòu)建針對內(nèi)分泌治療乳腺癌患者的服藥監(jiān)控平臺,采用隨機對照研究設(shè)計,患者被隨機分為實驗組157例和對照組154例。實驗組在常規(guī)護理的基礎(chǔ)上,實施基于藥物監(jiān)控平臺的護士隨訪。對照組采用常規(guī)隨訪模式,參加醫(yī)院的門診常規(guī)隨訪。分別評價兩組在3個月、6個月、18個月和24個月的服藥依從性和生活質(zhì)量。結(jié)果實驗組的服藥依從性評分分別在6個月、18個月、24個月較對照組顯著提高(P0.05),生活質(zhì)量問卷各個維度存在顯著的時間效應(yīng),但不具有組間差異(P0.05)。結(jié)論基于藥物監(jiān)控平臺的護士隨訪可提高內(nèi)分泌治療的乳腺癌患者的服藥依從性,但對改善總體生活質(zhì)量效果不明顯。
[Abstract]:Objective to explore the effect of nurse follow-up on endocrine compliance and quality of life in patients with breast cancer receiving endocrine therapy. Methods a drug monitoring platform for breast cancer patients with endocrine therapy was established. A randomized controlled study was designed. The patients were randomly divided into experimental group (157 cases) and control group (154 cases). On the basis of routine nursing, the experimental group carried out the follow-up of nurses based on the drug monitoring platform. The control group was followed up by routine follow-up. The compliance and quality of life of the two groups were evaluated in 3, 6, 18 and 24 months respectively. Results the scores of medication adherence in the experimental group were significantly higher than those in the control group at 6 months, 18 months, 24 months (P0.05). There was significant time effect in all dimensions of the quality of life questionnaire, but there was no difference between the two groups (P0.05). Conclusion nurse follow-up based on drug monitoring platform can improve the medication adherence of endocrine therapy breast cancer patients, but it has no obvious effect on improving the overall quality of life.
【作者單位】: 復旦大學護理學院;復旦大學附屬腫瘤醫(yī)院乳腺外科;復旦大學附屬腫瘤醫(yī)院護理部;
【基金】:上海市衛(wèi)生局局級科研項目(KBF400803)
【分類號】:R473.73
【正文快照】: 乳腺癌是女性最常見的腫瘤,占我國所有女性癌的15%,并且發(fā)病率呈逐年上升的趨勢[1]。內(nèi)分泌治療是乳腺癌主要全身治療手段之一。2012年美國國家綜合癌癥網(wǎng)絡(luò)(National Comprehensive CancerNetwork,NCCN)乳腺癌臨床實踐指南[2]建議,雌激素受體和(或)孕激素受體表達陽性的乳腺
【參考文獻】
相關(guān)期刊論文 前4條
1 朱葉卉;胡雁;吳密彬;陸箴琦;黃嘉玲;裘佳佳;;電話隨訪對乳腺癌患者服藥依從性和生活質(zhì)量的影響[J];中華護理雜志;2015年01期
2 張斯鈺;白麗瓊;譚紅專;楊華林;;Morisky服藥依從性量表在肺結(jié)核患者中的應(yīng)用[J];中國防癆雜志;2010年09期
3 鐘初雷;陶映;章澤豹;;醫(yī)院傳染病管理信息系統(tǒng)應(yīng)用研究[J];中華醫(yī)院感染學雜志;2005年12期
4 萬崇華,張冬梅,湯學良,張文莉,李文輝,任宏軒,和瑞生,王雯;乳腺癌患者生命質(zhì)量測定量表(FACT-B)中文版的修訂[J];中國心理衛(wèi)生雜志;2003年05期
【共引文獻】
相關(guān)期刊論文 前10條
1 付翠霞;馬麗麗;陳R,
本文編號:1339519
本文鏈接:http://sikaile.net/linchuangyixuelunwen/1339519.html
最近更新
教材專著